Anticancer agent 42

Anticancer agent 42(化合物10d)是一种口服有效的抗癌剂,对MDA-MB-231细胞具有较强抗肿瘤活性(IC50为0.07 μM),通过激活凋亡通路和p53表达发挥抗癌作用,可用于转移性乳腺癌的研究。
产品编号: MS-W64869 CAS No.: 2687265-18-3 分子式: C19H16Cl2N2O3 分子量: 391.25
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Anticancer agent 42(化合物10d)是一种口服有效的抗癌剂,对MDA-MB-231细胞具有较强抗肿瘤活性(IC50为0.07 μM),通过激活凋亡通路和p53表达发挥抗癌作用,可用于转移性乳腺癌的研究。

生物实验数据

生物活性 Anticancer agent 42 (compound 10d) is an orally active anticancer agent that exhibits potent antitumor activity against MDA-MB-231 cells with an IC50 of 0.07 μM, exerts its anticancer effects by activating apoptotic pathways and p53 expression, and can be used for research on metastatic breast cancer.
IC50 & Target

IC50: 0.07 μM (Anticancer in MDA-MB-231 cell)

体外研究
(In Vitro)

Anticancer agent 42 (compound 10d) (0-20 μM, 4 h) exhibits a potent antitumor activity against MDA-MB-231 cells.
Anticancer agent 42 (10 μM, 24 h) induces G2 and S phase arrest in MDA-MB-231 cells.
Anticancer agent 42 (10 μM, 24 h) induces cell apoptosis by regulating the expression of apoptosis related proteins in MDA-MB-231 cells.
Anticancer agent 42 (0-1 μM) depolarizes mitochondrial membrane and decreases the mitochondrial membrane potential leading to apoptosis.
Anticancer agent 42 (0-1 μM, 24 h) induces the cells to produce a large amount of ROS.

Cell Viability Assay

Cell Line: A549, MDA-MB-231, HeLa
Concentration: 0-20 μM
Incubation Time: 4 h
Result: Exhibited a potent activity against MDA-MB-231 with an IC50 of 0.07 μM.

Cell Cycle Analysis

Cell Line: MDA-MB-231 cells
Concentration: 10 μM
Incubation Time: 24 h
Result: Induced G2 and S phase arrest in MDA-MB-231 cells; caused the percentage of MDA-MB-231 cells in G1 phase to decrease significantly (from 74.44% to 16.48%), cells in G1 phase to increase (from 16.61% to 28.47%), and in G2 phase to significantly increase (from 8.95% to 55.05%).

Apoptosis Analysis

Cell Line: MDA-MB-231 cells
Concentration: 10 μM
Incubation Time: 24 h
Result: Induced cell apoptosis, with apoptotic rate of 31.69%.

Western Blot Analysis

Cell Line: MDA-MB-231 cells
Concentration: 100 nM
Incubation Time: 48 h
Result: Increased the level of human apoptosis-related proteins (pro-caspase 3, catalase, HTRA2/Omi and p53) in MDA-MB-231 cell.

Western Blot Analysis

Cell Line: MDA-MB-231 cells
Concentration: 0, 0.035, 0.07, 0.14, 0.21 μM
Incubation Time: 24 h
Result: Increased caspase 9, caspase3, cytochrome C and Bax expression, but decreased Bal-2 expression with increasing concentration.
体内研究
(In Vivo)

Anticancer agent 42 (compound 10d) (Kunming mice, 5000 mg/kg, Intragastric administration, once) has extremely low oral toxicity.
Anticancer agent 42 (Kunming mice, 238-600 mg/kg, IP, once) shows no obvious liver and kidney damage to mice, with an LD50 of 374 mg/kg.
Anticancer agent 42 (Kunming mice, 25 mg/kg, IP, once every two days) causes mild liver and kidney damage.
Anticancer agent 42 (BALB/c mice, suppresses breast cancer 4T1 tumor growth, the anti-tumor effect is better combined use with CA (Cyanoacrylates), and can cross through the skin to achieve anti-tumor effects..

Animal Model: Kunming mice (n=10, 5 male and 5 female)
Dosage: 5000 mg/kg
Administration: Intragastric administration, once
Result: Had extremely low oral toxicity, did not cause death in mice at 5000 mg/kg.
Animal Model: Kunming mice
Dosage: 600, 476, 378, 300, 238 mg/kg
Administration: IP, once
Result: Showed no obvious liver and kidney damage to mice, with an LD50 of 374 mg/kg.
Animal Model: Kunming mice (n=3)
Dosage: 25 mg/kg
Administration: IP, once every two days
Result: Caused mild liver and kidney damage after administration, slightly increased ALT, AST and BUN of mice.
Animal Model: BALB/c mice (4T1 tumor-bearing, female, eight groups, 6 mice per group)
Dosage: 10d (50 mg/kg) + CA; 10d (50 mg/kg) + saline; 10d (200 mg/kg) + CA
Administration: Intratumoral injection, every four days (50 mg/kg); smear, every two days (200 mg/kg), for 14 days.
Result: Showed obvious antitumor effect from the 8th day; had protective effects on the spleens of tumor-bearing mice; the anti-tumor effect is better when combined use with CA; can cross through the skin to achieve anti-tumor effects.

化学信息

分子量 391.25
分子式 C19H16Cl2N2O3
CAS No. 2687265-18-3

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础